These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35481309)

  • 1. Tocilizumab and Baricitinib for Recovery From Acute Exacerbation of Combined Pulmonary Fibrosis and Emphysema Secondary to COVID-19 Infection: A Case Report.
    Kai Y; Matsuda M; Suzuki K; Kasamatsu T; Kajita A; Uno K; Muro S
    Cureus; 2022 Mar; 14(3):e23411. PubMed ID: 35481309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.
    Suresh K; Figart M; Formeck S; Mehmood T; Abdel Salam M; Bassilly D
    J Investig Med High Impact Case Rep; 2021; 9():23247096211019557. PubMed ID: 34105382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Outcomes among Hospitalized COVID-19 Patients Who Received Baricitinib or Tocilizumab in Addition to Standard of Care.
    Walker CP; Hurlock NP; Deb S
    Diseases; 2024 May; 12(5):. PubMed ID: 38785762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab Versus Baricitinib for the Treatment of COVID-19 in Patients With Obesity.
    Troyer BS; Kovacic Scherrer N; Garavaglia J
    J Pharm Pract; 2024 Jun; 37(3):632-636. PubMed ID: 36803310
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation During Acute Respiratory Distress: A Case Report and Literature Review.
    Farooqi F; Dhawan N; Morgan R; Dinh J; Nedd K; Yatzkan G
    Trop Med Infect Dis; 2020 Jul; 5(3):. PubMed ID: 32635353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapse of COVID-19 and Viral Evolution in a Patient With Good Syndrome: A Case Report.
    Iwasaki M; Hashimoto M; Takeuchi JS; Kusaba Y; Kimura M; Terada-Hirashima J; Sugiura W; Hojo M
    Cureus; 2024 Jan; 16(1):e52592. PubMed ID: 38371040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial.
    Karampitsakos T; Papaioannou O; Tsiri P; Katsaras M; Katsimpris A; Kalogeropoulos AP; Malakounidou E; Zarkadi E; Tsirikos G; Georgiopoulou V; Sotiropoulou V; Koulousousa E; Chourpiliadi C; Matsioulas A; Lagadinou M; Sampsonas F; Akinosoglou K; Marangos M; Tzouvelekis A
    Clin Microbiol Infect; 2023 Mar; 29(3):372-378. PubMed ID: 36273769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab and PMX-DHP have efficacy for severe COVID-19 pneumonia.
    Shinomiya S; Nakase K; Fujii A; Takahara Y; Adachi H; Okuro M; Iinuma Y; Yokoyama H; Ito T; Mizuno S
    SAGE Open Med Case Rep; 2021; 9():2050313X21991063. PubMed ID: 33796310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study.
    Bryushkova EA; Skatova VD; Mutovina ZY; Zagrebneva AI; Fomina DS; Kruglova TS; Akopyan AA; Strazhesko ID; Lukyanov SA; Tkacheva ON; Lysenko MA; Chudakov DM
    PLoS One; 2022; 17(8):e0273340. PubMed ID: 36001576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19.
    Masiá M; Padilla S; García JA; García-Abellán J; Navarro A; Guillén L; Telenti G; Mascarell P; Botella Á; Gutiérrez F
    Front Med (Lausanne); 2021; 8():749657. PubMed ID: 34820393
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective study.
    Kojima Y; Nakakubo S; Kamada K; Yamashita Y; Takei N; Nakamura J; Matsumoto M; Horii H; Sato K; Shima H; Suzuki M; Konno S
    J Med Virol; 2022 Dec; 94(12):5702-5712. PubMed ID: 35916111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baricitinib versus tocilizumab in critically ill COVID-19 patients: A retrospective cohort study.
    Conroy GM; Bauer SR; Pallotta AM; Duggal A; Wang L; Sacha GL
    Pharmacotherapy; 2024 Jan; 44(1):28-38. PubMed ID: 37593883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NEUROPROTECTIVE AND ANTIOXIDANT POTENTIAL OF MONTELUKAST-ACETYLCYSTEINE COMBINATION THERAPY FOR BRAIN PROTECTION IN PATIENTS WITH COVID-19 INDUCED PNEUMONIA.
    Samsonia M; Kandelaki M; Baratashvili N; Gvaramia L
    Georgian Med News; 2023 Feb; (335):111-118. PubMed ID: 37042600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab as a Treatment for 'Cytokine Storm Syndrome' in COVID-19: A Case Report.
    Syam AF; Pitoyo CW; Suhendro S; Zulkarnain B; Indrasari ND; Aditianingsih D; Irawan C; Susilo A; Rumende CM; Wijaya IP; Ibrahim F; Rasmin M; Alwi I; Makmun D
    Acta Med Indones; 2021 Apr; 53(2):194-201. PubMed ID: 34251348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19-Associated Pulmonary Aspergillosis in a Patient Treated With Remdesivir, Dexamethasone, and Baricitinib: A Case Report.
    Shimada A; Ohnaka S; Kubo K; Nakashima M; Nagai A
    Cureus; 2022 Apr; 14(4):e23755. PubMed ID: 35518522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study.
    Kojima Y; Nakakubo S; Takei N; Kamada K; Yamashita Y; Nakamura J; Matsumoto M; Horii H; Sato K; Shima H; Suzuki M; Konno S
    Medicina (Kaunas); 2022 Apr; 58(4):. PubMed ID: 35454352
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of Tocilizumab vs Baricitinib in Clinical Outcomes Among Hospitalized Patients With COVID-19: Experience From a Public Hospital System in New York City.
    Sunny S; Tran A; Lee J; Abdallah M; Chaudhry N; Quale J
    Open Forum Infect Dis; 2023 Aug; 10(8):ofad426. PubMed ID: 37608917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.